×
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
NASDAQ:SLN

Silence Therapeutics News Headlines

$12.30
+1.21 (+10.91%)
(As of 06/29/2022 02:13 PM ET)
Add
Compare
Today's Range
$9.50
$12.60
50-Day Range
$7.99
$15.98
52-Week Range
$7.80
$26.99
Volume
1,007 shs
Average Volume
23,100 shs
Market Capitalization
$368.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.00
Get Silence Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.

SLN Media Mentions By Week

SLN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SLN
News Sentiment

0.93

0.40

Average
Medical
News Sentiment

SLN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SLN Articles
This Week

1

0

SLN Articles
Average Week



SLN Stock News Headlines Today

SourceHeadline
finance.yahoo.com logoSilence Therapeutics to Present at Jefferies Healthcare Conference
finance.yahoo.com - June 2 at 8:18 AM
seekingalpha.com logoSilence Therapeutics receives $2M in research milestone from Hansoh Pharma
seekingalpha.com - April 25 at 8:40 AM
finance.yahoo.com logoSilence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 6 at 8:24 AM
finance.yahoo.com logoSilence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting
finance.yahoo.com - April 3 at 2:48 PM
finance.yahoo.com logoSilence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)
finance.yahoo.com - April 3 at 2:48 PM
finanznachrichten.de logoSilence Therapeutics plc: Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
finanznachrichten.de - March 24 at 10:27 PM
seekingalpha.com logoSilence Therapeutics plc 2021 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 17 at 10:37 AM
finance.yahoo.com logoSilence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022
finance.yahoo.com - March 2 at 11:11 AM
finance.yahoo.com logoSilence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
finance.yahoo.com - February 21 at 4:12 PM
finance.yahoo.com logo8 Medical Stocks to Buy According to Mitchell Blutt’s Consonance Capital
finance.yahoo.com - February 15 at 5:23 PM
seekingalpha.com logoSilence Therapeutics' SLN360 for high Lipoprotein(a) shows promise in phase 1 trial
seekingalpha.com - February 9 at 10:28 AM
finance.yahoo.com logoSilence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)
finance.yahoo.com - February 9 at 10:28 AM
finance.yahoo.com logoSilence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo
finance.yahoo.com - January 26 at 8:50 AM
finance.yahoo.com logoNew Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases
finance.yahoo.com - December 12 at 10:16 AM
finance.yahoo.com logoSilence Therapeutics Welcomes Deep Track Capital as New Shareholder
finance.yahoo.com - December 1 at 8:22 AM
lse.co.uk logoSilence Therapeutics to proceed with AIM delisting next week
lse.co.uk - November 26 at 8:26 AM
proactiveinvestors.com logoSilence Therapeutics says US institutional investor buys US$20mln stake
proactiveinvestors.com - November 5 at 9:49 AM
finance.yahoo.com logoSilence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder
finance.yahoo.com - November 5 at 9:49 AM
finance.yahoo.com logoSilence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
finance.yahoo.com - October 21 at 10:38 AM
finance.yahoo.com logoSilence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform
finance.yahoo.com - October 15 at 7:12 AM
finance.yahoo.com logoSilence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market
finance.yahoo.com - October 15 at 7:12 AM
finance.yahoo.com logoSilence Therapeutics to Host R&D Day on October 21, 2021
finance.yahoo.com - October 7 at 8:50 AM
finance.yahoo.com logoSilence Therapeutics (LON:SLN) shareholders have earned a 36% CAGR over the last five years
finance.yahoo.com - September 13 at 9:02 AM
finance.yahoo.com logoSilence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development
finance.yahoo.com - September 1 at 11:43 AM
finance.yahoo.com logoSilence Therapeutics to Participate in September Investor Conferences
finance.yahoo.com - August 25 at 10:43 AM
fool.com logoSilence Therapeutics plc (SLN) Q2 2021 Earnings Call Transcript
fool.com - August 12 at 10:37 PM
finance.yahoo.com logoSilence Therapeutics Reports Half-Year 2021 Results
finance.yahoo.com - August 12 at 9:42 AM
proactiveinvestors.com logoSilence Therapeutics - Holding(s) in Company
proactiveinvestors.com - August 9 at 12:48 AM
proactiveinvestors.com logoSilence Therapeutics - Total Voting Rights
proactiveinvestors.com - August 7 at 11:15 PM
finance.yahoo.com logoSilence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration
finance.yahoo.com - May 25 at 8:31 AM
markets.businessinsider.com logoSilence Therapeutics' siRNA Candidate Reduces Plasma Iron Levels, Early-Stage Study Shows
markets.businessinsider.com - May 19 at 9:25 AM
markets.businessinsider.com logoThe Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics
markets.businessinsider.com - May 19 at 8:01 AM
finance.yahoo.com logoSilence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers
finance.yahoo.com - May 19 at 8:01 AM
finance.yahoo.com logoSilence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - May 12 at 7:22 AM
finance.yahoo.com logoSilence Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 7 at 7:45 AM
finance.yahoo.com logoSilence Therapeutics to Present at the Barclays Global Healthcare Conference
finance.yahoo.com - March 4 at 9:33 AM
finance.yahoo.com logoSilence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases
finance.yahoo.com - February 26 at 7:30 AM
markets.businessinsider.com logoSilence Therapeutics : First dosing for SLN360
markets.businessinsider.com - February 18 at 9:28 AM
finance.yahoo.com logoSilence Therapeutics to Present at the 2021 SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 18 at 9:28 AM
finance.yahoo.com logoSilence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)
finance.yahoo.com - February 17 at 7:20 AM
Get Silence Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:SLN) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.